Slovak biotech company Axon Neuroscience creates antibodies to stop COVID-19 from reproducing

By bne IntelliNews November 24, 2020

Slovak clinical-stage biotech company Axon Neuroscience has created therapeutic antibodies able to prevent reproduction of the coronavirus (COVID-19), with the efficacy of these antibodies successfully tested in cooperation with the Virology Institute of Slovak Academy of Sciences' Bio-medical Centre, said Michael Matis from Axon Neuroscience to the Slovak News Agency on November 23.

The company has already reported positive pre-clinical results of its vaccine against COVID-19 in September, tested on mice with no adverse side effects. Now, it has launched the process of humanisation, which is a prerequisite for clinical tests.

"While developing a vaccine, we created antibodies that we used to map out the virus's weak spots. Some of them were seen to eliminate the virus completely, thereby showing their therapeutic potential. Their efficacy was proven in several conceptually distinctive tests developed at our facility," said Axon's science director Norbert Zilka, quoted by the news agency. 

“We'll focus on the humanisation process as part of the next step, and then we could launch the production process,” Zilka added.

Related Articles

Druzhba oil flow to Slovakia and Hungary is renewed

The oil flow from the Russian Druzhba pipeline was renewed late on August 19. “The flow of oil to Slovakia is standard at the moment,” the country’s Minister of Economy Denisa Saková (Hlas) ... more

US Westinghouse could develop electricity storage site near Slovak Gabčíkovo hydroelectric power plant

US power company Westinghouse is reportedly in talks with the Slovak government to develop a new type of electricity storage site near the Gabčíkovo hydroelectric power plant (HPP) on the Danube ... more

Non-performing loans hit historic low in CESEE, but early warning signs emerge, says EBRD

Non-performing loans (NPLs) in central, eastern and south-eastern Europe (CESEE) fell to their lowest levels since the global financial crisis in 2024, but early indicators suggest rising risks ... more

Dismiss